Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
Atherosclerosis is the primary cause of cardiovascular diseases, such as myocardial infarction and stroke, which account for the highest death toll worldwide. Macrophage is the major contributor to atherosclerosis progression, and therefore, macrophage-associated pathological process is considered a...
Saved in:
Main Authors: | Ping Ping Hu (Author), Shuang Xue Luo (Author), Xiao Qing Fan (Author), Di Li (Author), Xiao Yong Tong (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Advances on targeted nanomedicines for atherosclerosis
by: Qinggong Han, et al.
Published: (2022) -
Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications
by: Xue Li, et al.
Published: (2022) -
Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy
by: Xuejia Kang, et al.
Published: (2023) -
Biomimetic nanomedicines for precise atherosclerosis theranostics
by: Ying Tao, et al.
Published: (2023) -
Macrophage Death as a Pharmacological Target in Atherosclerosis
by: Wim Martinet, et al.
Published: (2019)